ADMA Biologics, Inc.
ADMA Real Time Price USDRecent trades of ADMA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ADMA's directors and management
Government lobbying spending instances
-
$10,000 Apr 17, 2024 Issue: Defense
-
$10,000 Oct 20, 2023 Issue: Defense
-
$10,000 Jul 19, 2023 Issue: Defense
-
$10,000 Jan 18, 2023 Issue: Defense
-
$10,000 Oct 18, 2022 Issue: Defense
-
$10,000 Jul 14, 2022 Issue: Defense
-
$10,000 Apr 18, 2022 Issue: Defense
-
$10,000 Jan 18, 2022 Issue: Defense
-
$10,000 Oct 19, 2021 Issue: Health Issues Defense
-
$10,000 Apr 19, 2021 Issue: Health Issues Defense
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Aug. 10, 2021
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Jun. 16, 2020
-
Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Apr. 16, 2019
-
Patent Title: Compositions and methods for the treatment of immunodeficiency May. 15, 2018
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Nov. 14, 2017
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Jul. 25, 2017
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Aug. 18, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ADMA in WallStreetBets Daily Discussion
Recent insights relating to ADMA
Recent picks made for ADMA stock on CNBC
ETFs with the largest estimated holdings in ADMA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ADMA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.